Healthcare / BiotechnologyNasdaqGS
$9.04
-1.16 (-11.42%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-70.7M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$802M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-160.0%
↓Gross Margin
99.9%
↑Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-104.8%
FCF / Net income
0.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $67.5M · net income $-278.7M · FCF $-70.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $67.5M | $67.5M | $53.9M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | $-278.7M | $-278.7M | $-174.0M | $-152.6M | $-135.8M | $-130.5M | $-89.6M | $-63.1M | $-60.4M | $-35.4M | $-27.6M | $-22.6M | $-204691.00 | $-28611.00 | $-27315.00 | $-27040.00 | $-22395.00 | $-19996.00 | $-33623.00 | $-14977.00 |
| EBITDA | $-275.8M | $-275.8M | $-169.5M | $-150.2M | $-134.9M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -3.18 | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 99.9% | 99.9% | 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -449.9% | -449.9% | -358.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -412.9% | -412.9% | -322.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 0.12 | 0.12 | 0.04 | 0.04 | 0.03 | — | 0.01 | 0.03 | 0.05 | 0.07 | 0.13 | — | — | — | — | — | — | — | — | — |
| Current Ratio | 6.15 | 6.15 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $-70.7M | $-70.7M | $133.8M | $-125.0M | $-110.7M | $-105.7M | $-72.0M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||||
| ROE | -160.0% | -160.0% | -42.1% | -38.4% | -32.3% | -25.8% | -14.7% | -28.9% | -37.5% | -44.4% | -48.5% | -27.6% | 6.0% | 23.1% | 28.6% | 39.7% | 54.6% | 107.5% | -2401.6% | -42.8% |
| Valuation | ||||||||||||||||||||
| P/B | 4.55 | 4.55 | 1.82 | 2.76 | 1.94 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 25.2% | 25.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | -57.4% | -57.4% | 2.9% | -2.5% | — | -16.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+58.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.02 → -3.18
Residual
+58.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.